An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC). Data will be collected from patients who have received 1 course of standard systemic chemotherapy, experienced disease progression, and who are receiveingTarceva in a second-line setting. Patients will also be followed through third-line treatment if there is disease progression on Tarceva therapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Adult patients ≥ 18 years of age.

• Written informed consent.

• Recurrent or metastatic, Stage III or IV non-small cell lung cancer (NSCLC).

• Measurable disease (Response Evaluation Criteria In Solid Tumors).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

• Prior course of standard systemic chemotherapy.

Exclusion Criteria:

• Contra-indications to treatment with Tarceva.